Results 41 to 50 of about 561,319 (304)

Identification of DNA methylation prognostic signature of acute myelocytic leukemia.

PLoS ONE, 2018
BackgroundThe aim of this study is to find the potential survival related DNA methylation signature capable of predicting survival time for acute myelocytic leukemia (AML) patients.MethodsDNA methylation data were downloaded.
Haiguo Zhang, Guanli Song, Guanbo Song, Ruolei Li, Min Gao, Ling Ye, Chengfang Zhang   +6 more
doaj   +1 more source

Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China

Journal of Translational Medicine, 2020
Background Previous findings have indicated that the tumor, nodes, and metastases (TNM) staging system is not sufficient to accurately predict survival outcomes in patients with non-small lung carcinoma (NSCLC).
Rui-Qi Wang, Xiao-Ran Long, Chun-Lei Ge, Mei-Yin Zhang, Long Huang, Ning-Ning Zhou, Yi Hu, Rui-Lei Li, Zhen Li, Dong-Ni Chen, Lan-Jun Zhang, Zhe-Sheng Wen, Shi-Juan Mai, Hui-Yun Wang   +13 more
doaj   +1 more source

Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma

Frontiers in Cell and Developmental Biology, 2022
Background: Lung adenocarcinoma (LUAD) accounts for the majority of lung cancers, and the survival of patients with advanced LUAD is poor. The extracellular matrix (ECM) is a fundamental component of the tumor microenvironment (TME) that determines the ...
Lingyan Xiao, Qian Li, Yongbiao Huang, Zhijie Fan, Wan Qin, Bo Liu, Xianglin Yuan   +6 more
doaj   +1 more source

NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma. [PDF]

, 2019
The MYC oncogene is dysregulated in approximately 30% of liver cancer. In an effort to exploit MYC as a therapeutic target, including in hepatocellular carcinoma (HCC), strategies have been developed on the basis of MYC amplification or gene ...
Bodzin, Adam S., Budhu, Anuradha, Dang, Hien, Dominguez, Dana A., Lee, Ju-Seog, Martin, Sean P., Pomyen, Yotsawat, Shah, Ashesh P., Wang, Xin Wei, Yim, Sun Young   +9 more
core   +3 more sources

A taxonomy of epithelial human cancer and their metastases [PDF]

, 2009
Background: Microarray technology has allowed to molecularly characterize many different cancer sites. This technology has the potential to individualize therapy and to discover new drug targets.
Olivier Gevaert, Anneleen Daemen, Bart De Moor, Louis Libbrecht, CH Chung, TR Golub, B Weigelt, T Sorlie, DN Hayes, CM Perou, A Bhattacharjee, A Alizadeh, T Sorlie, S Ramaswamy, TJ Giordano, D Rhodes, S Ramaswamy, GV Glinsky, N Pavlidis, RW Tothill, RA Bender, G Bloom, XJ Ma, D Talantov, CL Wilson, M Dai, A Subramanian, G Dennis, DW Huang, PS Nelson, M Cuatrecasas, JH Eichhorn, SK Tickoo, G Ayala, J Brugarolas, P Staller, X Liu, BJ Yoder, M Lacroix, B Weigelt, C Sotiriou, EA Rakha, C Sotiriou, AV Ivshina, M Ignatiadis, JX Yu, Z Hu, EK Sloan, AK Witkiewicz, L Lukes, AK Witkiewicz, XJ Ma, K Pavlakis, S Troup, K Wennmalm, P Schedin, G Finak, KA Oien, HG Laberke, MB Amin, SJ Jung, RC Bast Jr, JD Seidman, H Kang, H Naora, SM Smorenburg, T Sukata, IJ Matouk, S Khambata-Ford, MA Pantaleo, DH Ki, A Ramasamy, M Snyder, J Belmont, K Chin, LD Miller, J Pittman   +76 more
core   +3 more sources

Survival-associated alternative splicing signatures in esophageal carcinoma

Carcinogenesis, 2018
Alternative splicing (AS), a major mechanism for the enhancement of transcriptome and proteome diversity, has been widely demonstrated to be involved in the full spectrum of oncogenic processes. High-throughput sequencing technology and the rapid accumulation of clinical data sets have provided an opportunity to systemically analyze the association ...
Shuangshuang, Mao, Yuan, Li, Zhiliang, Lu, Yun, Che, Shouguo, Sun, Jianbing, Huang, Yuanyuan, Lei, Xinfeng, Wang, Chengming, Liu, Sufei, Zheng, Ruochuan, Zang, Ning, Li, Jiagen, Li, Nan, Sun, Jie, He   +14 more
openaire   +2 more sources

Pancreatic cancer survival analysis defines a signature that predicts outcome.

PLoS ONE, 2018
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the US. Despite multiple large-scale genetic sequencing studies, identification of predictors of patient survival remains challenging.
Pichai Raman, Ravikanth Maddipati, Kian Huat Lim, Aydin Tozeren   +3 more
doaj   +1 more source

Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients

Cancer Cell International, 2019
Background Increasing evidences supported the association between long non-coding RNA (lncRNA) and disease free survival in gastric cancer (GC) patients.
Canchang Cheng, Qicai Wang, Minggu Zhu, Kelong Liu, Zhiqiao Zhang   +4 more
doaj   +1 more source

Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer

Frontiers in Oncology, 2021
BackgroundCervical cancer is one of the most common types of gynecological malignancies worldwide. This study aims to develop an immune signature to predict survival in cervical cancer.MethodThe gene expression data of 296 patients with cervical cancer ...
Yu Chen, Hao Lin, Ya-Nan Pi, Xi-Xi Chen, Hu Zhou, Yuan Tian, Wei-Dong Zhao, Bai-Rong Xia   +7 more
doaj   +1 more source

Prognostic impact of a lymphocyte activation-associated gene signature in GBM based on transcriptome analysis [PDF]

PeerJ, 2021
Background Glioblastoma multiforme (GBM) is a highly, malignant tumor of the primary central nervous system. Patients diagnosed with this type of tumor have a poor prognosis.
Yujia Lan, Erjie Zhao, Xinxin Zhang, Xiaojing Zhu, Linyun Wan, Suru A, Yanyan Ping, Yihan Wang   +7 more
doaj   +2 more sources